|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.790 USD | 0.00% |
|
-10.50% | +30.66% |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 617.8 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | 100.67% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | 432.1 | 517 | 511.8 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | 24.52% | 19.64% | -1.01% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -2.52x | -2.35x | -2.51x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 1.59x | 1.03x | 1.34x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0.1x | -0.31x | 0.38x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 92,628x | 42.3x | 5.75x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | 64,789x | 35.4x | 4.76x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | -2.17x | -2.19x | -1.88x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | -2.01x | -2.1x | -2.16x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | -2.77x | -3.02x | -3.83x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | -36.1% | -33.1% | -26.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.7095 | -0.7627 | -0.7129 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 0.00667 | 14.59 | 107.5 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -198.7 | -235.9 | -271.5 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -214.7 | -246.7 | -236.6 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -197.3 | -231.1 | -225.9 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -185.7 | -100.8 | -106 |
| Reference price 2 | 14.920 | 6.290 | 3.210 | 2.130 | 1.370 | 1.790 | 1.790 | 1.790 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 345,155 | - | - |
| Announcement Date | 2/23/22 | 2/28/23 | 3/14/24 | 3/13/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.52x | 64788.94x | -2.17x | -.--% | 618M | |
| 32.53x | 8.12x | 25.44x | 0.05% | 53.83B | |
| 19.5x | 6.01x | 13.15x | 1.63% | 52.1B | |
| -42.48x | 13.5x | -39.59x | -.--% | 23.48B | |
| -18.22x | 4.32x | -7.57x | -.--% | 23.13B | |
| 24.24x | 4.75x | 12.54x | -.--% | 19.36B | |
| 24.39x | 4.78x | 15.56x | -.--% | 17.56B | |
| 45.88x | 18.59x | 47.88x | 0.08% | 15.2B | |
| -505.73x | 35.47x | -1462.84x | -.--% | 14.83B | |
| 17.57x | 5.11x | 11.88x | -.--% | 14.06B | |
| Average | -40.48x | 6,488.96x | -138.57x | 0.18% | 23.42B | |
| Weighted average by Cap. | -18.41x | 180.43x | -82.56x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
